headlinez.news Live news trend intelligence
↑ Rising Health

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

Takeda’s Qdenga has become the first dengue vaccine to receive official approval in India for use among residents aged 4 to 60.

7sources
8articles
5velocity
+89%since first seen
8h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

The Drug Controller General of India (DCGI) has granted approval for the use of the Qdenga vaccine, manufactured by the Japanese pharmaceutical company Takeda. The vaccine is indicated for individuals between the ages of 4 and 60.

Coverage from Reuters, The Hindu, The Indian Express, NDTV, and The Times of India emphasizes the scope of the approval and the vaccine's eligibility requirements. Media reports also highlight that a private university located in a city conducted chemical trials related to the vaccine.

Future developments will depend on the implementation of the vaccine rollout. Current coverage does not yet specify the timeline for public availability or distribution protocols for the newly approved treatment.

Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.

Quick answers

Who is eligible to receive the Qdenga vaccine?

The vaccine is approved for individuals aged 4 to 60 years.

Which organization approved the vaccine?

The Drug Controller General of India (DCGI) granted the approval.

What is the origin of the vaccine?

Qdenga is produced by the Japanese drugmaker Takeda.

Coverage (8)

Topics

Related trends